NEW YORK, NY / ACCESSWIRE / January 25, 2018 / Cerus shares skyrocketed to a new high on Wednesday after the company announced positive results from its clinical trial of Intercept. Halozyme Therapeutics suffered a random loss without any specific news. The company will be releasing its fourth quarter financial results on February 20th.
RDI Initiates Coverage on:
Halozyme Therapeutics, Inc.
Cerus Corporation shares were winning big in Wednesday trading and closed the day up almost 16% on higher volume compared to usual. The stock also soared to a new high of $5.43 during intra-day trading. The company announced that a late-stage clinical trial with 86 patients, that was evaluating its Intercept treatment for chronic anemia patients that have thalassemia, had produced positive results. According to Cerus, individuals in the trial with Intercept-treated red blood cells met the trial's primary efficacy and safety endpoints. Cerus is planning to file for commercialization in Europe in the second half of this year. Last November the FDA granted the company permission to begin a much larger, 600-patient study to assess the ability of Intercept-treated RBCs to reduce kidney injury among patients undergoing heart surgeries. Shares of the stock have been rallying over the last three months with gains of nearly 75%.
Access RDI's Cerus Corporation Research Report at:
Halozyme Therapeutics, Inc. shares closed down 4.47% on fairly average volume yesterday. There was no remarkable news from the company to explain the losses but earlier in the week Halozyme announced it will webcast its Quarterly Update Conference Call for the fourth quarter 2017 on Tues., Feb. 20, after the market closes. The biotech company is developing novel oncology and drug-delivery therapies and has a lead proprietary program, an investigational drug called PEGPH20, applies a unique approach to targeting solid tumors. It allows increased access of co-administered cancer drug therapies to the tumor in animal models. The treatment is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies.
Access RDI's Halozyme Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute